5 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.
In this prospective observational data-collection study with retrospective data analysis, 80 subjects, who have been admitted at the UMC Utrecht because of a surgery, will be recruited at the pre-operative screening clinic before surgery. Prior to…
The primary objective is to evaluate the accuracy of the SpO2 measurements by the ViQtor compared to matched SaO2 measurements obtained during a hypoxic measurements to obtain the root mean square (ARMS) for a range of skin types defined by…